Effective Ablation of Pancreatic Cancer Cells in SCID Mice Using Systemic Adenoviral RIP-TK/GCV Gene Therapy

Journal of Surgical Research

Volumn 141, Issue 1, 2007, Pages 45-52

  Liu, Shi He ^a   Davis, Alan ^a   Li, Zhijun ^a   Ballian, Nikiforos ^a   Davis, Elizabeth ^a   Wang, Xiao Ping ^a   Fisher, William ^a   Brunicardi, F Charles ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

adenovirus; apoptosis; diabetes; gene therapy; pancreatic cancer; pancreatic polypeptide; PDX 1; rat insulin promoter

Indexed keywords

ADENOVIRUS SUBTYPE 5 MEDIATED RAT INSULIN PROMOTER DIRECTED THYMIDINE KINASE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; GANCICLOVIR; PANCREAS POLYPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL COUNT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MORPHOLOGY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS ISLET DELTA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; TREATMENT DURATION; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; CELL LINE, TUMOR; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GANCICLOVIR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HOMEODOMAIN PROTEINS; HUMANS; INJECTIONS, INTRAPERITONEAL; ISLETS OF LANGERHANS; MALE; MICE; MICE, SCID; PANCREATIC NEOPLASMS; THYMIDINE KINASE; TRANS-ACTIVATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34250160223     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.02.041     Document Type: Article

References (40)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer Statistics, 2004. CA Cancer J Clin 54 (2004) 8
2. Lowenfels A.B., and Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 34 (2004) 238
3. Blaszkowsky L. Treatment of advanced and metastatic pancreatic cancer. Front Biosci 3 (1998) E214
4. Fulda S., and Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 (2006) 4798
5. Tamada K., Wang X.P., and Brunicardi F.C. Molecular targeting of pancreatic disorders. World J Surg 29 (2005) 325
6. Wang X.P., Yazawa K., Templeton N.S., et al. Intravenous delivery of liposome-mediated nonviral DNA is less toxic than intraperitoneal delivery in mice. World J Surg 29 (2005) 339
7. Wang J., Lu X.X., Chen D.Z., et al. Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer. World J Gastroenterol 10 (2004) 400
8. Wang X.P., Yazawa K., Yang J., et al. Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter. J Gastrointest Surg 8 (2004) 98 Discussion 106
9. Makinen K., Loimas S., Wahlfors J., et al. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer. J Gene Med 2 (2000) 361
10. Carrio M., Romagosa A., Mercade E., et al. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene. Gene Ther 6 (1999) 547
11. Hajri A., Wack S., Lehn P., et al. Combined suicide gene therapy for pancreatic peritoneal carcinomatosis using BGTC liposomes. Cancer Gene Ther 11 (2004) 16
12. Poulsen T.T., Pedersen N., and Poulsen H.S. Replacement and suicide gene therapy for targeted treatment of lung cancer. Clin Lung Cancer 6 (2005) 227
13. Tong X.W., Kieback D.G., Ramesh R., et al. Molecular aspects of ovarian cancer. Is gene therapy the solution?. Hematol Oncol Clin North Am 13 (1999) 109
14. Li Z., Ding Q., Li Y., et al. Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant. Cancer Lett 236 (2006) 58
15. Deharvengt S., Wack S., Aprahamian M., et al. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy. J Gene Med 7 (2005) 672
16. Yang L., Cao Z., Li F., et al. Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther 11 (2004) 1215
17. Tirone T.A., Fagan S.P., Templeton N.S., et al. Insulinoma-induced hypoglycemic death in mice is prevented with β cell-specific gene therapy. Ann Surg 233 (2001) 603
18. Tirone T.A., Wang X.P., Templeton N.S., et al. Cell-specific cytotoxicity of human pancreatic adenocarcinoma cells using rat insulin promoter thymidine kinase-directed gene therapy. World J Surg 28 (2004) 826
19. Wesseling J.G., Yamamoto M., Adachi Y., et al. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther 8 (2001) 990
20. Harris J.D., Gutierrez A.A., Hurst H.C., et al. Gene therapy for cancer using tumor-specific pro-drug activation. Gene Ther 1 (1994) 170
21. Facfarlane W.M., Shepherd R.M., Cosgrove K.E., et al. Glucose modulation of insulin mRNA levels is dependent on transcription factor PDX-1 and occurs independently of changes in intracellular Ca2+. Diabetes 49 (2000) 418
22. Glick E., Leshkowitz D., and Walker M.D. Transcription factor β2 acts cooperatively with E2A and PDX1 to activate the insulin gene promoter. J Biol. Chem 275 (2000) 2199
23. Ohneda K., Mirmira R.G., Wang J., et al. The homeo domain of PDX-1 mediates multiple protein-protein interactions in the formation of a transcriptional activation complex on the insulin promoter. Mol Cell Biol 20 (2000) 900
24. Dumonteil E., Laser B., Constant I., et al. Differential regulation of the glucagon and insulin I gene promoters by the basic helix-loop-helix transcription factors E47 and β-2. J Biol Chem 273 (1998) 19945
25. Gerrish K., Gannon M., Shih D., et al. Pancreatic β cell-specific transcription of the pdx-1 gene. J Biol Chem 275 (2000) 3485
26. Koizumi M., Doi R., Toyoda E., et al. Increased PDX-1 expression is associated with outcome in patients with pancreatic cancer. Surgery 134 (2003) 260
27. Liu S., Wang X.P., and Brunicardi F.C. Enhanced cytotoxicity of RIPTK gene therapy of pancreatic cancer via PDX-1 codelivery. J Surg Res 137 (2007) 1
28. Davis A.R., Meyers K., and Wilson J.M. High throughput method for creating and screening recombinant adenoviruses. Gene Ther 5 (1998) 1148
29. Song J.S., Kim H.P., Yoon W.S., et al. Adenovirus-mediated suicide gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter induced apoptosis of ovarian cancer cell line. Biosci Biotechnol Biochem 67 (2003) 2344
30. Chen J.F., Huang Z.H., Huang Y.Y., et al. Construction of recombinant adenoviruses encoding TK suicide gene driven by VEGF promoter using efficient AdEasier-1 system. Ai Zheng 23 (2004) 1093
31. Wang J., Yao M., Zhang Z., et al. Enhanced suicide gene therapy by chimeric tumor-specific promoter based on HSF1 transcriptional regulation. FEBS Lett 546 (2003) 315
32. Yoshimura I., Ikegami S., Suzuki S., et al. Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. J Urol 168 (2002) 2659
33. Vorburger S.A., and Hunt K.K. Adenoviral gene therapy. Oncologist 7 (2002) 46
34. Ghosh S.S., Gopinath P., and Ramesh A. Adenoviral vectors: A promising tool for gene therapy. Appl Biochem Biotechnol 133 (2006) 9
35. Relph K.L., Harrington K.J., and Pandha H. Adenoviral strategies for the gene therapy of cancer. Semin Oncol 32 (2005) 573
36. Aoki K., Yoshida T., Matsumoto N., et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 8 (1997) 1105
37. Ramirez P.J., and Vickers S.M. Adenoviral gene therapy for pancreatic adenocarcinoma. Curr Surg 61 (2004) 351
38. Seymour N.E., Brunicardi F.C., Chaiken R.L., et al. Reversal of abnormal glucose production after pancreatic resection by pancreatic polypeptide administration in man. Surgery 104 (1988) 119
39. Lundqvist A., Noffz G., Pavlenko M., et al. Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection. J Immunother 25 (2002) 445
40. Miyatsuka T., Kaneto H., Shiraiwa T., et al. Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation. Genes Dev 20 (2006) 1435